Orforglipron for High Blood Pressure with Obesity or Overweight
This study is testing a medicine called Orforglipron (LY3502970) in people who have high blood pressure (hypertension) and are also overweight or have obesity. Researchers want to see if Orforglipron is safe and if it can help lower blood pressure. Some participants will receive Orforglipron, and others will receive a placebo (an inactive substance like a sugar pill). The main thing researchers will measure is how much your systolic blood pressure (the top number in a blood pressure reading) changes from the start of the study to Week 36. Adults aged 18 and older can potentially join. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 487 participants. It compares Orforglipron to a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for changes in blood pressure up to Week 36.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
At a glance
Conditions
Where it's being run
99 sites across 28 statesStudy leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change from Baseline in office Systolic Blood Pressure (SBP)Baseline to Week 36